Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stevanato Group S.p.A. Ordinary Shares (NY:STVN)

14.10 -5.64 (-28.57%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stevanato Group S.p.A. Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Stevanato (STVN) Q3 2026 Earnings Call Transcript ↗
Biologics demand held firm while GLP-1 volumes shape the 2027 outlook. 
Via The Motley Fool
Topics Earnings
US Stock Gap Movers: Up and Down Names in Today's Session ↗
Via Chartmill
News headline image
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato Group to Participate in Two Upcoming Investor Conferences
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato Group Q2 Earnings Call Highlights ↗
Stevanato Group (NYSE:STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its... 
Via MarketBeat
Topics Earnings
News headline image
Stevanato (STVN) Q2 2026 Earnings Call Transcript ↗
Revenue grew 8% as high-value solutions surged 16%, driving adjusted EBITDA up 21%. 
Via The Motley Fool
Topics Earnings
News headline image
Stevanato Group Q2 2026 Earnings Call: Complete Transcript ↗
Stevanato Group (NYSE:STVN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call... 
Via Benzinga
Topics Earnings
News headline image
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
From Stevanato Group S.p.A
Via Business Wire
News headline image
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now ↗
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now. 
Via The Motley Fool
Topics Economy
News headline image
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
From Stevanato Group
Via Business Wire
News headline image
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato (STVN) Q1 2026 Earnings Transcript ↗
Stevanato (STVN) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics World Trade
News headline image
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato Group to Participate in Three Upcoming Investor Conferences
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
From Stevanato Group
Via Business Wire
News headline image
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
From Stevanato Group S.p.A.
Via Business Wire
News headline image
End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces Retirement
Shares of West Pharmaceutical Services (NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends... 
Via MarketMinute
Topics Economy Retirement
News headline image
Stevanato (STVN) Q4 2025 Earnings Call Transcript ↗
Stevanato (STVN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
From Stevanato Group S.p.A.
Via Business Wire
News headline image
Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026
From Stevanato Group
Via Business Wire
News headline image
The Biotech Revolution’s Ultimate ‘Picks and Shovels’ Play: A Deep Dive into West Pharmaceutical Services (WST)
As the pharmaceutical industry undergoes its most significant transformation in decades, the spotlight often falls on the blockbuster drugs themselves—the weight-loss miracles and the life-saving... 
Via MarketMinute
Topics Economy
News headline image
Picks and Shovels of the Biotech Revolution: A Deep Dive into West Pharmaceutical Services (WST)
Date: December 23, 2025 Introduction In the high-stakes world of biotechnology and pharmaceutical manufacturing, few companies are as indispensable yet as quietly influential as West Pharmaceutical... 
Via PredictStreet
Topics Economy Intellectual Property Supply Chain
News headline image
Stevanato (STVN) Q3 2025 Earnings Call Transcript ↗
Stevanato (STVN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Stevanato Group SPA (NYSE:STVN) Tops Q3 2025 Earnings and Revenue Estimates ↗
Stevanato Group (STVN) beat Q3 2025 earnings and revenue estimates, driven by record high-value solutions and strong demand for its syringes. 
Via Chartmill
News headline image
Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025
From Stevanato Group S.p.A.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.